^
Association details:
| Biomarker: | NRAS mutation + BRAF wild-type |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) + exarafenib (KIN-2787) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in combination with MEK inhibition in preclinical models of human NRAS mutant melanoma.
Published date:
05/26/2022
Excerpt:
...we evaluated NRAS mutant, BRAF WT melanoma for combination potential with binimetinib. Melanoma tumor cell lines bearing NRAS hotspot mutations demonstrated synergistic benefit with KIN-2787 combined with binimetinib.
DOI:
10.1200/JCO.2022.40.16_suppl.e15099
